Progress in the study of polycythemia vera in children

Liang-Jia HU, Wen-Yu YANG

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (7) : 898-903.

PDF(519 KB)
HTML
PDF(519 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (7) : 898-903. DOI: 10.7499/j.issn.1008-8830.2511004
REVIEW

Progress in the study of polycythemia vera in children

Author information +
History +

Abstract

Pediatric polycythemia vera is an exceedingly rare myeloproliferative neoplasm characterized by clonal overgrowth of the erythroid lineage. Although research on adult polycythemia vera is relatively well established, standardized diagnostic and therapeutic protocols for pediatric patients are lacking. Due to substantial differences in physiological characteristics and disease progression between children and adults, directly applying adult treatment regimens is not appropriate. Pediatric-specific management strategies tailored to the unique features of children are urgently needed. This article systematically reviews the etiology, clinical manifestations, diagnostic methods, and therapeutic advances of pediatric polycythemia vera, aiming to provide evidence to support clinical decision-making and basic research.

Key words

Polycythemia vera / Myeloproliferative neoplasm / Thrombosis / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Liang-Jia HU , Wen-Yu YANG. Progress in the study of polycythemia vera in children[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(7): 898-903 https://doi.org/10.7499/j.issn.1008-8830.2511004

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2023, 98(4): 681-689. DOI: 10.1002/ajh.26828 .
https://www.ncbi.nlm.nih.gov/pubmed/36601682
Cited in this article [1]
[2]
Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States[J]. Leuk Lymphoma, 2022, 63(3): 694-702. DOI: 10.1080/10428194.2021.1992756 .
https://www.ncbi.nlm.nih.gov/pubmed/34689695
Cited in this article [1]
[3]
Hultcrantz M, Ravn Landtblom A, Andréasson B, et al. Incidence of myeloproliferative neoplasms: trends by subgroup and age in a population-based study in Sweden[J]. J Intern Med, 2020, 287(4): 448-454. PMCID: PMC7598815. DOI: 10.1111/joim.13019 .
https://www.ncbi.nlm.nih.gov/pubmed/31927786
Cited in this article [1]
[4]
Ianotto JC, Curto-Garcia N, Lauermanova M, et al. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review[J]. Haematologica, 2019, 104(8): 1580-1588. PMCID: PMC6669170. DOI: 10.3324/haematol.2018.200832 .
https://www.ncbi.nlm.nih.gov/pubmed/30679326
Cited in this article [6]
[5]
Duek A, Berla M, Ellis MH. Recent advances in the treatment of polycythemia vera[J]. Leuk Lymphoma, 2022, 63(8): 1801-1809. DOI: 10.1080/10428194.2022.2057491 .
https://www.ncbi.nlm.nih.gov/pubmed/35387553
Cited in this article [1]
[6]
Bader MS, Meyer SC. JAK2 in myeloproliferative neoplasms: still a protagonist[J]. Pharmaceuticals (Basel), 2022, 15(2): 160. PMCID: PMC8874480. DOI: 10.3390/ph15020160 .
https://www.ncbi.nlm.nih.gov/pubmed/35215273
Cited in this article [1]
[7]
Zhang Y, Zhao Y, Liu Y, et al. New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms[J]. Cancer, 2024, 130(24): 4229-4240. DOI: 10.1002/cncr.35559 .
https://www.ncbi.nlm.nih.gov/pubmed/39277798
Cited in this article [1]
[8]
Alshemmari SH, Rajan R, Ameen R, et al. Analysis of common driver mutations in Philadelphia-negative myeloproliferative neoplasms[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(7): 483-488. DOI: 10.1016/j.clml.2021.03.005 .
https://www.ncbi.nlm.nih.gov/pubmed/33858806
Cited in this article [1]
[9]
Tremblay D, Kremyanskaya M, Mascarenhas J, et al. Diagnosis and treatment of polycythemia vera: a review[J]. JAMA, 2025, 333(2): 153-160. PMCID: PMC11921015. DOI: 10.1001/jama.2024.20377 .
https://www.ncbi.nlm.nih.gov/pubmed/39556352
Cited in this article [1]
[10]
Ishida H, Miyajima Y, Hyakuna N, et al. Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: a retrospective nationwide survey[J]. EJHaem, 2020, 1(1): 86-93. PMCID: PMC9175656. DOI: 10.1002/jha2.39 .
https://www.ncbi.nlm.nih.gov/pubmed/35847744
Cited in this article [1]
[11]
Picard A, Bayart S, Deparis M, et al. Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatricians[J]. Eur J Pediatr, 2025, 184(2): 173. PMCID: PMC11794414. DOI: 10.1007/s00431-025-05993-1 .
https://www.ncbi.nlm.nih.gov/pubmed/39903357
Cited in this article [1]
[12]
Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications[J]. Leukemia, 2010, 24(9): 1574-1579. DOI: 10.1038/leu.2010.148 .
https://www.ncbi.nlm.nih.gov/pubmed/20631743
Cited in this article [1]
[13]
Shimano KA, Vanderpoel V, Stone H, et al. Clinical features associated with thrombotic events in children with myeloproliferative neoplasms[J]. Am J Hematol, 2022, 97(9): E353-E355. PMCID: PMC9378702. DOI: 10.1002/ajh.26646 .
https://www.ncbi.nlm.nih.gov/pubmed/35751861
Cited in this article [1]
[14]
Rutherford K, Farnoud N, Krishnan A, et al. Mutational profile of children with myeloproliferative neoplasms[J]. Blood, 2022, 140(S1): 3991-3992. DOI: 10.1182/blood-2022-164732 .
Cited in this article [1]
[15]
Ismael O, Shimada A, Hama A, et al. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children[J]. Pediatr Blood Cancer, 2012, 59(3): 530-535. DOI: 10.1002/pbc.23409 .
https://www.ncbi.nlm.nih.gov/pubmed/22106054
Cited in this article [1]
[16]
Sobas M, Kiladjian JJ, Beauverd Y, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs[J]. Blood Adv, 2022, 6(17): 5171-5183. PMCID: PMC9631631. DOI: 10.1182/bloodadvances.2022007201 .
https://www.ncbi.nlm.nih.gov/pubmed/35802458
Cited in this article [1]
[17]
Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1 545 patients with contemporary polycythemia vera: an international study[J]. Leukemia, 2013, 27(9): 1874-1881. PMCID: PMC3768558. DOI: 10.1038/leu.2013.163 .
https://www.ncbi.nlm.nih.gov/pubmed/23739289
Cited in this article [1]
[18]
Enblom-Larsson A, Renlund H, Andréasson B, et al. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera: a matched nationwide population-based study[J]. Br J Haematol, 2024, 204(5): 1740-1751. DOI: 10.1111/bjh.19337 .
https://www.ncbi.nlm.nih.gov/pubmed/38351734
Cited in this article [1]
[19]
Cario H, Mcmullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera[J]. Ann Hematol, 2009, 88(8): 713-719. PMCID: PMC4135082. DOI: 10.1007/s00277-009-0758-y .
https://www.ncbi.nlm.nih.gov/pubmed/19468728
Cited in this article [1]
[20]
Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet[J]. Leukemia, 2018, 32(5): 1057-1069. PMCID: PMC5986069. DOI: 10.1038/s41375-018-0077-1 .
https://www.ncbi.nlm.nih.gov/pubmed/29515238
Cited in this article [1]
[21]
Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients[J]. Blood Cancer J, 2017, 7(12): 662. PMCID: PMC5802551. DOI: 10.1038/s41408-017-0035-6 .
https://www.ncbi.nlm.nih.gov/pubmed/29282357
Cited in this article [1]
[22]
Debureaux PE, Cassinat B, Soret-dulphy J, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses[J]. Blood Adv, 2020, 4(15): 3708-3715. PMCID: PMC7422133. DOI: 10.1182/bloodadvances.2020002414 .
https://www.ncbi.nlm.nih.gov/pubmed/32777065
Cited in this article [1]
[23]
Lee MW, Yeon SH, Ryu H, et al. Volumetric splenomegaly in patients with polycythemia vera[J]. J Korean Med Sci, 2022, 37(11): e87. PMCID: PMC8938613. DOI: 10.3346/jkms.2022.37.e87 .
https://www.ncbi.nlm.nih.gov/pubmed/35315598
Cited in this article [2]
[24]
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms[J]. Leukemia, 2022, 36(7): 1703-1719. PMCID: PMC9252913. DOI: 10.1038/s41375-022-01613-1 .
https://www.ncbi.nlm.nih.gov/pubmed/35732831
Cited in this article [1]
[25]
Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms[J]. Am J Hematol, 2023, 98(3): 544-545. DOI: 10.1002/ajh.26821 .
https://www.ncbi.nlm.nih.gov/pubmed/36600640
Cited in this article [1]
[26]
Mcmullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis[J]. Br J Haematol, 2005, 130(2): 174-195. DOI: 10.1111/j.1365-2141.2005.05535.x .
https://www.ncbi.nlm.nih.gov/pubmed/16029446
Cited in this article [1]
[27]
Kilinç YC, Bolat A, Gürsel O, et al. Etiology, diagnosis, and genetic analysis of polycythemia in pediatric population[J]. Indian J Hematol Blood Transfus, 2025, 41: 538-544. PMCID: PMC12267764. DOI: 10.1007/s12288-024-01887-8 .
https://www.ncbi.nlm.nih.gov/pubmed/40687473
Cited in this article [1]
[28]
Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia[J]. Br J Haematol, 2002, 117(1): 47-53. DOI: 10.1046/j.1365-2141.2002.03386.x .
https://www.ncbi.nlm.nih.gov/pubmed/11918532
Cited in this article [1]
[29]
McMullin MF. Congenital erythrocytosis[J]. Int J Lab Hematol, 2016, 38 (): 59-65. DOI: 10.1111/ijlh.12506 .
https://www.ncbi.nlm.nih.gov/pubmed/27161533
Cited in this article [1] Abstract
Suppl 1
[30]
Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet[J]. J Clin Oncol, 2011, 29(6): 761-770. PMCID: PMC4979120. DOI: 10.1200/jco.2010.31.8436 .
https://www.ncbi.nlm.nih.gov/pubmed/21205761
Cited in this article [1]
[31]
Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations[J]. Lancet Haematol, 2022, 9(4): e301-e311. DOI: 10.1016/S2352-3026(22)00046-1 .
https://www.ncbi.nlm.nih.gov/pubmed/35358444
Cited in this article [1]
[32]
Choi HS, Hong J, Hwang SM, et al. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms[J]. Ann Hematol, 2021, 100(10): 2567-2574. DOI: 10.1007/s00277-021-04527-7 .
https://www.ncbi.nlm.nih.gov/pubmed/34331110
Cited in this article [1]
[33]
Gisslinger H, Klade C, Georgiev P, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment[J]. Leukemia, 2023, 37(10): 2129-2132. PMCID: PMC10539163. DOI: 10.1038/s41375-023-02008-6 .
https://www.ncbi.nlm.nih.gov/pubmed/37634011
Cited in this article [1]
[34]
Kucine N, Bergmann S, Krichevsky S, et al. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia[J]. Pediatr Blood Cancer, 2021, 68(3): e28888. PMCID: PMC9040312. DOI: 10.1002/pbc.28888 .
https://www.ncbi.nlm.nih.gov/pubmed/33381905
Cited in this article [1]
[35]
Basquiera AL, Pizzi S, Correas AG, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina[J]. Pediatr Blood Cancer, 2015, 62(1): 153-157. DOI: 10.1002/pbc.25238 .
https://www.ncbi.nlm.nih.gov/pubmed/25264233
Cited in this article [1]
[36]
Stoops K, Kuril S. Ruxolitinib in a child with JAK2 exon 12 mutant polycythemia vera[J]. J Pediatr Hematol Oncol, 2023, 45(4): e502-e505. DOI: 10.1097/MPH.0000000000002549 .
https://www.ncbi.nlm.nih.gov/pubmed/36161965
Cited in this article [2]
[37]
Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial[J]. J Clin Oncol, 2023, 41(19): 3534-3544. PMCID: PMC10306428. DOI: 10.1200/JCO.22.01935 .
https://www.ncbi.nlm.nih.gov/pubmed/37126762
Cited in this article [1]
[38]
Sørensen AL, Skov V, Kjær L, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera[J]. Blood Adv, 2024, 8(20): 5416-5425. PMCID: PMC11526083. DOI: 10.1182/bloodadvances.2024013170 .
https://www.ncbi.nlm.nih.gov/pubmed/39163611
Cited in this article [1]
[39]
Ginzburg Y, Kirubamoorthy K, Salleh S, et al. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy[J]. Blood, 2021, 138(S1): 390. DOI: 10.1182/blood-2021-149205 .
Cited in this article [1]
[40]
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera[J]. Expert Opin Investig Drugs, 2020, 29(6): 525-536. PMCID: PMC7534842. DOI: 10.1080/13543784.2020.1761323 .
https://www.ncbi.nlm.nih.gov/pubmed/32693648
Cited in this article [1]

Footnotes

所有作者均声明无利益冲突。

PDF(519 KB)
HTML

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉